INmune Bio Reports Q4 2025 Earnings with Increased Net Loss but Progress on Key Programs
INmune Bio (NASDAQ: INMB) reported a net loss of $45.9 million for Q4 2025, up from the previous year's $42.1 million. The company reduced R&D expenses and raised capital through equity offerings to fund operations until early 2027. Despite setbacks in Alzheimer’s trials, progress was made on CORDStrom regulatory submissions and positive results were seen in its INKmune program.
Tickers: $INMB
Topics: biotech capital_raising clinical_trials R&D_expenses